Basic Information
| RNALocate ID: | RLID:11001913 |
| RNA Symbol: | hsa-miR-149-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-149 |
| RNA ID: | miRBase:MIMAT0000450 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 18589210 |
| Tissue/Cell Line: | Primary ovarian tumor cells|Serum |
| Method: | MACS|Microarray |
| Description: | Exosomal miRNAs as potential biomarkers and therapeutic targets. Data are collected from Table 1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001831 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001832 | Mitochondrion | Myotube | 27396686 |
| RLID:01001833 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01001834 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001835 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11001914 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001915 | Exosome | Breast milk | 22211110 |
| RLID:11001916 | Exosome | Brain tissue | 23382797 |
| RLID:11001917 | Exosome | Plasma | 23663360 |
| RLID:11001918 | Exosome | Serum | 24683445 |
| RLID:11001919 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11001920 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000098 | Exosome | Endothelial cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000378 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-149-5p | Diffuse large b cell lymphoma | MNDR-E-MI-16311 |
| MNDR | hsa-miR-149-5p | Oral squamous cell carcinoma | MNDR-E-MI-16312 |
| MNDR | hsa-miR-149-5p | Follicular lymphoma | MNDR-E-MI-16313 |
| MNDR | hsa-miR-149-5p | Medulloblastoma | MNDR-E-MI-16314 |
| MNDR | hsa-miR-149-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-16315 |
| MNDR | hsa-miR-149-5p | Lymphoma | MNDR-E-MI-16316 |
| MNDR | hsa-miR-149-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-16317 |
| MNDR | hsa-miR-149-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-16318 |
| MNDR | hsa-miR-149-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-16319 |
| MNDR | hsa-miR-149-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-16320 |
| MNDR | hsa-miR-149-5p | Breast cancer luminal | MNDR-E-MI-16321 |
| MNDR | hsa-miR-149-5p | Anencephaly | MNDR-E-MI-16322 |
| MNDR | hsa-miR-149-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-16323 |
| MNDR | hsa-miR-149-5p | Dermatomyositis | MNDR-E-MI-16324 |
| MNDR | hsa-miR-149-5p | Prostate cancer | MNDR-E-MI-16325 |
| MNDR | hsa-miR-149-5p | Gastric cancer | MNDR-E-MI-16326 |
| MNDR | hsa-miR-149-5p | Alzheimer disease | MNDR-E-MI-16327 |
| MNDR | hsa-miR-149-5p | Intracranial aneurysm | MNDR-E-MI-16328 |
| MNDR | hsa-miR-149-5p | Dysautonomia familial | MNDR-E-MI-16329 |
| MNDR | hsa-miR-149-5p | Polycystic ovary syndrome | MNDR-E-MI-16330 |
| MNDR | hsa-miR-149-5p | Leukemia | MNDR-E-MI-16331 |
| MNDR | hsa-miR-149-5p | Lung cancer | MNDR-E-MI-16332 |
| MNDR | hsa-miR-149-5p | Parkinson disease | MNDR-E-MI-16333 |
| MNDR | hsa-miR-149-5p | Breast cancer | MNDR-E-MI-16334 |
| MNDR | hsa-miR-149-5p | Neuroendocrine neoplasia | MNDR-E-MI-16335 |
| MNDR | hsa-miR-149-5p | Thyroid cancer | MNDR-E-MI-16336 |
| MNDR | hsa-miR-149-5p | Pituitary neoplasms | MNDR-E-MI-16337 |
| MNDR | hsa-miR-149-5p | Pancreatic cancer | MNDR-E-MI-16338 |
| MNDR | hsa-miR-149-5p | Melanoma | MNDR-E-MI-16339 |
| MNDR | hsa-miR-149-5p | Williams syndrome | MNDR-E-MI-16340 |
| MNDR | hsa-miR-149-5p | Rectum adenocarcinoma | MNDR-E-MI-16341 |
| MNDR | hsa-miR-149-5p | Nephroblastoma | MNDR-E-MI-16342 |
| MNDR | hsa-miR-149-5p | Colon cancer | MNDR-E-MI-16343 |
| MNDR | hsa-miR-149-5p | Colon adenocarcinoma | MNDR-E-MI-16344 |
| MNDR | hsa-miR-149-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-16345 |
| MNDR | hsa-miR-149-5p | Familial ovarian cancer | MNDR-E-MI-16346 |
| MNDR | hsa-miR-149-5p | Prostate adenocarcinoma | MNDR-E-MI-16347 |
| MNDR | hsa-miR-149-5p | Pulmonary tuberculosis | MNDR-E-MI-16348 |
| MNDR | hsa-miR-149-5p | Glioblastoma | MNDR-E-MI-16349 |
| MNDR | hsa-miR-149-5p | Astrocytoma | MNDR-E-MI-16350 |
| MNDR | hsa-miR-149-5p | Glioma | MNDR-E-MI-16351 |
| MNDR | hsa-miR-149-5p | Oligodendroglioma | MNDR-E-MI-16352 |
| MNDR | hsa-miR-149-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-16353 |
| MNDR | hsa-miR-149-5p | Osteosarcoma | MNDR-E-MI-16354 |
| MNDR | hsa-miR-149-5p | Liposarcoma | MNDR-E-MI-16355 |
| MNDR | hsa-miR-149-5p | Coronary artery disease | MNDR-E-MI-16356 |
| MNDR | hsa-miR-149-5p | Inclusion body myositis | MNDR-E-MI-16357 |
| MNDR | hsa-miR-149-5p | Breast carcinoma | MNDR-E-MI-16358 |
| MNDR | hsa-miR-149-5p | Infarction middle cerebral artery | MNDR-E-MI-16359 |
| MNDR | hsa-miR-149-5p | Uterine cancer | MNDR-E-MI-16360 |
| MNDR | hsa-miR-149-5p | Cervical adenocarcinoma | MNDR-E-MI-16361 |
| MNDR | hsa-miR-149-5p | Gastric adenocarcinoma | MNDR-E-MI-16362 |
| MNDR | hsa-miR-149-5p | Cervical squamous cell carcinoma | MNDR-E-MI-16363 |
| MNDR | hsa-miR-149-5p | Pituitary adenoma | MNDR-E-MI-16364 |
| MNDR | hsa-miR-149-5p | Lung squamous cell carcinoma | MNDR-E-MI-16365 |
| MNDR | hsa-miR-149-5p | Carcinoma lung non-small-cell | MNDR-E-MI-16366 |
| MNDR | hsa-miR-149-5p | Lung adenocarcinoma | MNDR-E-MI-16367 |
| MNDR | hsa-miR-149-5p | Thyroid carcinoma | MNDR-E-MI-16368 |
| MNDR | hsa-miR-149-5p | Ovarian carcinoma | MNDR-E-MI-16369 |
| MNDR | hsa-miR-149-5p | Bladder urothelial carcinoma | MNDR-E-MI-16370 |
| MNDR | hsa-miR-149-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-16371 |
| MNDR | hsa-miR-149-5p | Carcinoma renal cell | MNDR-E-MI-16372 |
| MNDR | hsa-miR-149-5p | Renal clear cell carcinoma | MNDR-E-MI-16373 |
| MNDR | hsa-miR-149-5p | Cholangiocarcinoma | MNDR-E-MI-16374 |
| MNDR | hsa-miR-149-5p | Esophageal cancer | MNDR-E-MI-16375 |
| MNDR | hsa-miR-149-5p | Lung small cell carcinoma | MNDR-E-MI-16376 |
| MNDR | hsa-miR-149-5p | Synovial sarcoma | MNDR-E-MI-16377 |
| MNDR | hsa-miR-149-5p | T acute lymphoblastic leukemia | MNDR-E-MI-16378 |
| MNDR | hsa-miR-149-5p | Acute t cell leukemia | MNDR-E-MI-16379 |
| MNDR | hsa-miR-149-5p | Hepatocellular carcinoma | MNDR-E-MI-16380 |
| MNDR | hsa-miR-149-5p | Familiar ovarian carcinoma | MNDR-E-MI-16381 |
| MNDR | hsa-miR-149-5p | Malignant pleural mesothelioma | MNDR-E-MI-16382 |
| MNDR | hsa-miR-149-5p | Acute myelocytic leukemia | MNDR-E-MI-16383 |
| MNDR | hsa-miR-149-5p | Colorectal cancer | MNDR-E-MI-16384 |
| MNDR | hsa-miR-149-5p | Nasopharyngeal carcinoma | MNDR-E-MI-16385 |
| MNDR | hsa-miR-149-5p | Acute lymphocytic leukemia | MNDR-E-MI-16386 |
| MNDR | hsa-miR-149-5p | Ependymoma | MNDR-E-MI-16387 |
| MNDR | hsa-miR-149-5p | Cardiomegaly | MNDR-E-MI-16388 |
| MNDR | hsa-miR-149-5p | Nasopharyngeal cancer | MNDR-E-MI-16389 |
| MNDR | hsa-miR-149-5p | Prostatic neoplasms | MNDR-E-MI-16390 |
| MNDR | hsa-miR-149-5p | Stroke | MNDR-E-MI-16391 |
| MNDR | hsa-miR-149-5p | Stroke lacunar | MNDR-E-MI-16392 |
| MNDR | hsa-miR-149-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-16393 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | BBC3 | Homo sapiens | RR00212851 |
TOP